Current and future etiologic therapy of bacterial pneumonia. 1. Antibiotic therapy for community-acquired pneumonia

А.Е. Abaturov, Т.А. Kryuchko

Abstract


The progressive increase in the prevalence of respiratory infections caused by multiresistant pathogenic agents is a serious problem requiring strict indications and development of algorithms for prescribing antibacterial drugs for pneumonia treatment. Amoxicillin is a drug of choice for the treatment of community-acquired pneumonia with a mild and uncomplicated course in children. The indications for prescribing macrolides are the patient’s allergy to β-lactam antibiotics or suspect mycoplasmal or chlamydial etiology of pneumonia. The choice of amoxicillin/clavulanate or cephalosporins for oral administration is proved by the laboratory data or a clinical suspicion of pneumonia caused by pathogens producing β-lactamases. The treatment strategy with the use of non-antibiotic agents for antibiotic-associated diseases therapy is being actively developed currently.

Keywords


community-acquired pneumonia; children; antibacterial drugs

References


Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014 Apr;12(4):300-8. doi: 10.1038/nrmicro3232.

Aminov R. History of antimicrobial drug discovery: Major classes and health impact. Biochem Pharmacol. 2017 Jun 5. pii: S0006-2952(16)30331-8. doi: 10.1016/j.bcp.2016.10.001.

Arshad H, Fasanya A, Cheema T, Singh AC. Acute Pneumonia. Crit Care Nurs Q. 2016 Apr-Jun;39(2):148-60. doi: 10.1097/CNQ.0000000000000108.

Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):617-30. doi: 10.1093/cid/cir625.

Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):e25-76. doi: 10.1093/cid/cir531.

Breuer O, Blich O, Cohen-Cymberknoh M, et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015 May;50(5):495-502. doi: 10.1002/ppul.23159.

Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J. 2016 Jul;35(7):752-9. doi: 10.1097/INF.0000000000001159.

Cilloniz C, Martin-Loeches I, Garcia-Vidal C, et al. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. Int J Mol Sci. 2016 Dec 16;17(12). pii: E2120. doi: 10.3390/ijms17122120.

Esposito S, Cohen R, Domingo JD, et al Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J. 2012 Jun;31(6):e78-85. doi: 10.1097/INF.0b013e318255dc5b.

Fernández-Mormontoy J, Estremadoyro-Gallardo A, Vargas OF. Mortality predictive scores for community-acquired pneumonia in children. Pediatr Pulmonol. 2017 Apr 11. doi: 10.1002/ppul.23706.

Haq IJ, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in children. BMJ. 2017 Mar 2;356:j686. doi: 10.1136/bmj.j686.

Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011 Oct;66 Suppl 2:ii1-23. doi: 10.1136/thoraxjnl-2011-200598.

Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother. 2009;63:511-9. doi: 10.1093/jac/dkn538.

Hazir T, Fox LM, Nisar YB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency tria. Lancet. 2008 Jan 5;371(9606):49-56. doi: 10.1016/S0140-6736(08)60071-9.

Hüseyin K, Akyol S, Parkan ÕM, et al. Molecular characterization and antibiotic susceptibility of Haemophilus influenzae clinical isolates. Infez. Med. 2017 Mar 1;25(1):27-32. PMID: 28353452.

Kealey C, Creaven CA, Murphy CD, Brady CB. New approaches to antibiotic discovery. Biotechnol Lett. 2017 Jun;39(6). doi: 10.1007/s10529-017-2311-8.

Laopaiboon M., Panpanich R., Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev. 2015 Mar 8;(3):CD001954. doi: 10.1002/14651858.CD001954.pub4.

Lassi ZS, Das JK, Haider SW, et al. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014 Jul;99(7):687-93. doi: 10.1136/archdischild-2013-304023.

Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis.. Lancet. 2015 Jan 31;385(9966):430-40. doi: 10.1016/S0140-6736(14)61698-6.

Lodha R, Randev S, Kabra SK. Oral Antibiotics for Community acquired Pneumonia with Chest indrawing in Children Aged Below Five Years: A Systematic Review. Indian Pediatr. 2016 Jun 8;53(6):489-95. PMID: 27376603.

Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015 Mar;70(3):213-22. doi: 10.1016/j.jinf.2014.10.004.

Nijnik A, Hancock R. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J. 2009;2:e1. doi: 10.3134/ehtj.09.001.

Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016 Jun 22;7:974. doi: 10.3389/fmicb.2016.00974.

Pelton SI, Jacobs MR, authors. Pneumococcal Infections. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 7th ed. Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Philadelphia: Saunders; 2014. pp. 1198-1245.

Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 2014. WHO Guidelines Approved by the Guidelines Review Committee.

Ribeiro CF, Ferrari GF, Fioretto JR. Antibiotic treatment schemes for very severe community-acquired pneumonia in children: a randomized clinical study. Rev Panam Salud Publica. 2011 Jun;29(6):444-50. PMID: 21829969.

Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007 Mar;57(3 Suppl):5S–12S. doi: 10.1016/j.diagmicrobio.2006.12.014.

Vincent JL, Bassetti M, François B, et al. Advances in antibiotic therapy in the critically ill. Crit Care. 2016 May 17;20(1):133. doi: 10.1186/s13054-016-1285-6.

Xaba SN, Greeff O, Becker P. Determinants, outcomes and costs of ceftriaxone v. amoxicillin-clavulanate in the treatment of community-acquired pneumonia at Witbank Hospital. S Afr Med J. 2014 Mar;104(3):187-91. PMID: 24897821.




DOI: https://doi.org/10.22141/2224-0551.12.3.2017.104231

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru